Display options
Cite
Kangas-Dick A, Berger AC, Koshenkov V. ASO Author Reflections: Gene Expression Profiling for Melanoma: Is it Ready for Prime Time?. Ann Surg Oncol. 2021;28(8):4590-4591doi: 10.1245/s10434-021-09599-3.
Kangas-Dick, A., Berger, A. C., & Koshenkov, V. (2021). ASO Author Reflections: Gene Expression Profiling for Melanoma: Is it Ready for Prime Time?. Annals of surgical oncology, 28(8), 4590-4591. https://doi.org/10.1245/s10434-021-09599-3
Kangas-Dick, Aaron, et al. "ASO Author Reflections: Gene Expression Profiling for Melanoma: Is it Ready for Prime Time?." Annals of surgical oncology vol. 28,8 (2021): 4590-4591. doi: https://doi.org/10.1245/s10434-021-09599-3
Kangas-Dick A, Berger AC, Koshenkov V. ASO Author Reflections: Gene Expression Profiling for Melanoma: Is it Ready for Prime Time?. Ann Surg Oncol. 2021 Aug;28(8):4590-4591. doi: 10.1245/s10434-021-09599-3. Epub 2021 Jan 21. PMID: 33479864.
Copy Download .nbib Format: NLM
Share it on

Ann Surg Oncol. 2021 Aug;28(8):4590-4591. doi: 10.1245/s10434-021-09599-3. Epub 2021 Jan 21.

ASO Author Reflections: Gene Expression Profiling for Melanoma: Is it Ready for Prime Time?.

Annals of surgical oncology

Aaron Kangas-Dick, Adam C Berger, Vadim Koshenkov

Affiliations

  1. Division of Surgical Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA. [email protected].
  2. Department of Surgery, Maimonides Medical Center, Brooklyn, NY, USA. [email protected].
  3. Division of Surgical Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.

PMID: 33479864 DOI: 10.1245/s10434-021-09599-3

[No abstract available.]

References

  1. Gershenwald JE, Scolyer RA, Hess KR, et al. Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017;67(6):472–92. https://doi.org/10.3322/caac.21409 . - PubMed
  2. Gerami P, Cook RW, Wilkinson J, et al. Development of a prognostic genetic signature to predict the metastatic risk associated with cutaneous melanoma. Clin Cancer Res. 2015;21(1):175–83. https://doi.org/10.1158/1078-0432.ccr-13-3316 . - PubMed
  3. Zager JS, Gastman BR, Leachman S, et al. Performance of a prognostic 31-gene expression profile in an independent cohort of 523 cutaneous melanoma patients. BMC Cancer. 2018;18(1):1–11. https://doi.org/10.1186/s12885-018-4016-3 . - PubMed
  4. Kangas-Dick AW, Greenbaum A, Gall V, et al. Evaluation of a gene expression profiling assay in primary cutaneous melanoma. Ann Surg Oncol. 2021. https://doi.org/10.1245/s10434-020-09563-7 . - PubMed
  5. Kovarik CL, Chu EY, Adamson AS. Gene expression profile testing for thin melanoma. JAMA Dermatology. 2020;156(8):837. https://doi.org/10.1001/jamadermatol.2020.0894 . - PubMed

MeSH terms

Publication Types